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Abstract
Members of the NF-kB transcription factor family are differentially expressed in the B cell lineage.
Disruption of individual or two NF-kB subunits exhibits distinct defects in B lymphocyte
development, activation, and survival. However, the role each NF-kB plays during B cell
development has been obscured by molecular compensation. To address this issue, a trans-
dominant form of IkBα was transduced into bone marrow cells to act as a pan-inhibitor of NF-kB
using a retroviral system. While the development of T-lymphocytes and myeloid cell lineages was
not grossly affected by the transduced IkBα gene, a significant reduction in the number and
percentage of B lineage cells was apparent in IkBα transduced chimeric mice. IkBα expression
decreased the percentage of pre-B and immature B cell subsets in the bone marrow and further
impaired the development of follicular mature B cells and marginal zone B cells in the periphery.
Introduction of the Bcl-X transgene completely restored the pre-B and immature B cell pool in the
bone marrow. However, despite a significant improvement of overall viability of the B cell lineage,
Bcl-X expression was insufficient to overcome the maturation block resulting from NF-kB
inhibition. Together, our study suggests that NF-kB activity is required for two distinct checkpoints
during B cell development: one is for pre-B/immature B cell viability, the other is to provide both
survival and maturation signals to ensure the proper development of follicular mature B cells.
Introduction
Glucocorticoid hormones were the first agents to be used
as immunosuppressives, now more than 50 years ago.
Since their introduction they have been the cornerstones
used in most immunosuppressive treatment regimens for
the prevention of organ transplant rejection, and the sup-
pression of inflammation due to allergy and autoimmu-
nity. Nowell first reported an explanation for the
immunosuppressive action of glucocorticoids in 1961,
when he found that they markedly inhibited lymphocyte
proliferation in response to mitogenic lectins [1]. This was
traced to an efficient inhibition of the production of inter-
leukin 2 (then termed T Cell Growth Factor) by mitogen
or antigen activated T cells almost 20 years later [2].
A major advance in understanding of the molecular basis
of the effect of glucocorticoids on the expression of IL2
and other cytokine genes was reported by several groups
working independently about 10 years ago, when it was
found that glucocorticoid receptors physically interacted
with NF-kB and as well induced the expression of the
Inhibitor of NF-kB (IkB) [3-6]. Glucocorticoids have also
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been shown to inhibit other transcription factors, includ-
ing AP-1 and NFAT [7]. Because there is an overall NF-kB
suppression of transcription, the effects of glucocorticoids
are protean and dramatic on many tissues, and thus their
use as immunosuppressive agents is limited.
In an attempt to identify the roles played by the various
members of the NF-kB family in the development and
function of the immune system, we and others have
explored the effects of the targeted disruption of the indi-
vidual members of the NF-kB family. Our efforts have
focused on c-Rel, the only member of the NF-kB family
restricted to expression in the hematopoietic system. Mice
lacking the c-Rel gene were found to have apparently nor-
mal lymphoid development, but there are profound
defects in the antigen-induced proliferation, survival, and
cytokine production by T cells and B cells [8]. By compar-
ison, other members of the NF-kB family were found to
play significant roles in the development or maturation of
lymphocytes and hematopoietic cells. Because glucocorti-
coids inhibit the activation of all members of the NF-kB
family, we sought to mimic the effects of glucocorticoids
by the expression of activated IkB in hematopoietic pre-
cursor cells.
B cell development proceeds with several checkpoints that
ensure the proper assembly of surface antigen receptors
with non-self reactivity. In the bone marrow, the pre-BCR
signals the rearrangement of the light chain and subse-
quent differentiation into immature B cells. Immature B
cells bearing antigen receptor with self-reactivity are elim-
inated by negative selection process both in bone marrow
and periphery. In the periphery, the newly immigrated
Transitional B cells (CD24-hi/IgM+/IgD-lo) can be further
subdivided into T1 (CD21-, CD23-) and T2 (CD21+,
CD23+) groups based on CD21 and CD23 expression [9-
12], or into T1, T2, T3 groups by including the additional
marker AA4 [11]. Extracellular factors such as Blys pro-
duced by myeloid cells in the spleen and lymph nodes
prolong the survival of T2 and mature B cell subsets in the
periphery [13-16], while the differentiation of T2 cells
into follicular mature B cells may require both Blys and
BCR signals [17].
It has been well established that components of pre-BCR
and BCR signaling pathways are required for B cell devel-
opment. For instance, deletion of Igα, Igβ or Igµ chain
arrests B cell development at the pro-B stage [18-20],
while conditional deletion of the BCR on mature B cells
leads to rapid loss of B cells, suggesting that basal BCR
activity is required for mature B cell survival [21]. Further-
more, deletion of BCR signaling molecules, such as the
tyrosine kinases Syk and Btk, severely affect the matura-
tion of follicular B cells [22].
NF-kB is one of the key transcription factors activated by
Pre-BCR and BCR signals. Not surprisingly, disruption of
NF-kB members has been shown to impair BCR-mediated
proliferation, survival, and Ig class switching [8,23,24].
Five members of the NF-kB transcription factor family
(p50, p52, p65, c-Rel, RelB) display unique expression
patterns and functional roles in the development of
hematopoietic system, as revealed by the knockout mouse
studies. Each of these five members is also subject to dif-
ferent regulation by IkB kinase (IKK) [8,23,24]. The
IKK(β,α,γ) complex is primarily responsible for the activa-
tion of the NF-kB members, such as p50, p65, c-Rel, via
the conventional pathway. By contrast, the IKKα complex
is responsible for regulating the alternative pathway via its
unique function in p100 processing and generation of the
p52 complex [23,25-27].
Accordingly, individual NF-kB subsets play distinct roles
in the maturation of the B cell compartment [8]. Initial
studies using cell lines derived from various B cell differ-
entiation stages demonstrated that p50/p65 is the major
inducible complex in pre-B cells and non-lymphoid cells
[28]. Mature B cells, however, constitutively express c-Rel
in the nucleus (in addition to p50 and p65), while termi-
nally differentiated plasma cells and LPS-differentiated B
cells express all five isoforms (p52, RelB, c-Rel, p50, and
p65). Studies revealed that p50/p65 is essential for B cell
development as fetal liver cells derived from p50/p65
double knockout mice are blocked in development at an
early precursor stage and are unable to generate B and T
lymphocytes [29]. Co-transfer of wild type bone marrow
cells rescues lymphoid development in p50/p65 double
knockout mice, suggesting that a cell-extrinsic factor is
responsible for the defect [29].
The B cell lineage of p50/p52 double knockout mice also
have a developmental block, in this case occurring at the
immature T1 stage (IgM++, IgD-, CD21-, CD23-) due to
an inability to receive Blys (BAFF) receptor signals
[26,30,31]. It was later demonstrated that the Blys recep-
tor could activate the alternative NF-kB signaling pathway,
by inducing p100 processing into active p52 complexes
[27,32]. Deletion of both p65 and c-Rel perturbs the
repopulation of the IgM-lo/IgD-hi mature B cell popula-
tion which can be rescued by the expression of a Bcl-2
transgene, suggesting roles for c-Rel and p65 in mature B
cell survival [33,34]. p50 and c-Rel appear to regulate
mature lymphocyte functions rather than early stage
events, since combined deletion of p50 and c-Rel impairs
the proliferation and survival of mature B cells without
affecting early hematopoiesis [35,36]. Finally, the devel-
opment of MZ B cells is completely absent in p50 knock-
out mice and significantly reduced in c-Rel(-/-) mice or
p65(-/-) fetal liver reconstituted mice [37], suggesting thatMedical Immunology 2004, 3 http://www.medimmunol.com/content/3/1/1
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multiple NF-kB members are involved in MZ B cell
differentiation.
While the existing data suggest that both intrinsic and
extrinsic cellular defects are accountable for many of the B
cell developmental impairments observed in NF-kB
knockout mice, several issues remain to be defined. First,
due to molecular compensation, it is still inconclusive as
to whether the residual NF-kB members compensate for
certain missing individual activities. For example, Pre-
BCR signaling may depend on redundant NF-kB activity
for differentiation into immature B cells, as suggested by
the NF-kB site occupancy in the Igκ enhancer in pre-B cells
[38]. Surprisingly however, none of the NF-kB double
knockout mice have impaired development of early B cell
precursors in the bone marrow. In addition, the periph-
eral B cell maturation deficit observed in p65/c-Rel dou-
ble knockout chimeras has been mainly attributed to a
survival defect. However, the potential role of other NF-kB
members (especially p50/p52) in the differentiation proc-
ess prior to maturation into follicular B cells has not been
addressed.
Here, we report the use of a pan-NF-kB inhibitor, IkBα, to
block all NF-kB activity in bone marrow derived precursor
cells. We show that expression of a dominant active form
of IkBα significantly impairs B cell development at two
stages: first at the pre-B expansion stage, the second occur-
ring at transitional B cell maturation stage in the periph-
ery. Furthermore, NF-kB not only contributes to
Transfection efficiency, viral titer, and infection efficiency Figure 1
Transfection efficiency, viral titer, and infection efficiency Three plasmids (pHIT123, pCGP and MIGR1 or MIGR1-IkB) 
were transfected into 293T cell for 48 hours. The supernatant was collected and tested for viral titer by using NIH3T3 cell line. 
The viral supernatant was subsequently used for infecting bone marrow cells. Flow cytometry was performed to determine the 
transfection efficiency on 293T cells (A), viral titer on 3T3 cells (B), and viral infection efficiency on bone marrow cells (C) 
prior to transfer into lethally-irradiated recipient mice.
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IkBα overexpression leads to a reduction in the Pre-B/immature B cell compartment in the bone marrow Figure 2
IkBα overexpression leads to a reduction in the Pre-B/immature B cell compartment in the bone marrow Bone 
marrow cells were isolated from the MIGR1 control and IkBα-transduced chimeras at two and four weeks post-BM transplan-
tation. Cells were stained with biotin-conjugated B220 (A) or co-stained with PE-conjugated CD43 and biotin-conjugated 
B220 antibodies (B) and analyzed by flow cytometry. For (B), B220+ and CD43+ populations were assessed based on the 
GFP+ population. The data is a representative of five experiments.
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IkBα overexpression impairs the maturation of follicular and marginal zone B cells in the spleen Figure 3
IkBα overexpression impairs the maturation of follicular and marginal zone B cells in the spleen Purified splenic 
B cells (>95% B220+) were isolated from the MIGR1 control and IkBα-transduced chimeras two and four weeks after bone 
marrow transplantation. (A) Cells were co-stained with biotin-conjugated CD21 and PE-conjugated CD23 antibodies and ana-
lyzed by flow cytometry. After gating on GFP+ population, the percentage of follicular B cells (CD21+/CD23+), marginal zone 
B cells (CD21+/CD23-), and transitional B cells (CD21-/CD23-) were enumerated. (B) Cells were co-stained with biotin-con-
jugated CD24 and PE-conjugated IgM antibodies and analyzed by flow cytometry. After gating on GFP+ population, the per-
centage of Transitional immature B cells (CD24-hi, IgM+) and mature B cells (CD24-lo, IgM+) were enumerated. (C) Cells 
were co-stained with biotin-conjugated CD21 and PE-conjugated IgM antibodies and analyzed by flow cytometry. After gating 
on the GFP+ population, the percentage of Transitional 1 B cells (CD21-, IgM+) and more mature B cells (CD21+, IgM+, con-
taining T2, FB, and MZ B cells) were enumerated.
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Bcl-X completely rescues the Pro-B to Pre-B transition in IkBα-transduced chimeras Figure 4
Bcl-X completely rescues the Pro-B to Pre-B transition in IkBα-transduced chimeras Bone marrows derived from 
Bcl-X transgenic (WTtg) and non-transgenic (WT) mice were infected with MIGR1 control and IkBα-viruses in vitro and trans-
ferred to lethally-irradiated recipients as described in Materials and Methods. Two and four weeks after bone marrow trans-
plantation, reconstituted bone marrow cells were isolated from the MIGR1 control and IkBα-transduced chimeras. Cells were 
stained with biotin-conjugated B220 (A) or co-stained with PE-conjugated CD43 and biotin-conjugated B220 antibodies (B) 
followed by flow cytometry. For (B), the percentage of cells expressing B220 and CD43 was determined based on the GFP+ 
population.
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immature B cell survival but also is required for matura-
tion of follicular B cells. Accordingly, by inducing the
expression of IkB, glucocorticoids have a profound effect
on B-cell development and function, in addition to its
already well-described effect of preventing T-cell prolifer-
ation and differentiation by blocking NF-kB activation of
T cell cytokine gene expression.
Materials and methods
Preparation of retrovirus and determination of virus titer
A human cDNA encoding for the IkBα without amino
acids 1–36 was inserted into the MIGR1 plasmid, which
contains an MSV promoter and GFP [39,40]. The target
gene and GFP gene were separated by IRES and can be
expressed separately. The plasmids were cotransfected
with pHIT123 and PCGP into 293T cell by using calcium
phosphate method. The 293T cells were seeded the previ-
ous day to give a maximum of 70% confluence/plate on
the day of transfection. Ten micrograms of each plasmid
was used for each transfection. At 48 hours post transfec-
tion, the supernatant was harvested and assayed for viral
titer by infection on NIH3T3 cells. The retrovirus superna-
tant was stored at -80°C for future use.
Generation of chimeric mice with bone marrows infected 
with IkBα and control viruses
Female C57BL/6 mice (8–10 weeks old) were purchased
from The Jackson Labs (USA) and kept in specific patho-
gen-free conditions. C57BL/6 mice were injected with 5-
fluorouracil (5-FU, 250 mg/kg weight) per animal for 4
days. Bone marrow cells (BMCs) were isolated from tibias
and femurs of mice and suspended in DMEM with 5%
heat-inactivated fetal calf serum (FCS). Red blood cells
were depleted using ACK lysis buffer [41]. These BMCs
were cultured in 6-well plate with a cocktail of cytokines,
IL3 (6 ng/ml), IL6 (10 ng/ml) and SCF (100 ng/ml), for
one day. Then the retrovirus supernatant was added into
the BMCs, and cultured for an additional 4–6 days. Cells
were then collected and transferred into lethally irradiated
mice (850 Rad). Bone marrow chimeras were analyzed at
week 2, 4, 6 post-transfer.
Antibodies
Flow cytometric analyses of surface markers on hematopi-
etic cells were performed on FACScan instruments (Bec-
ton Dickinson). PE- or biotin-conjugated antibodies
specific for B220 (PE or biotin), IgM (PE), CD23 (PE),
CD21 (Biotin), Gr-1 (PE), CD11b (PE), CD4 (PE) and
CD8 (PE) were obtained from Pharmingen (San Diego,
CA). Thy 1.2 (biotin), and the Tricolour-conjugated
streptavidin was obtained from CALTAG (Burlingame,
CA).
Electrophoretic mobility shift assay (EMSA)
The nuclear and cytosolic fractionation procedure was
prepared as previously described [28]. Purified B lym-
phocytes (1 × 107 cells per treatment) were harvested,
washed once with PBS, resuspended into 100 µl of Buffer
A {10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl
and 0.5 mM DTT} plus 0.1% NP-40. Cells were lysed on
ice for 2 min and checked for complete lysis under the
microscope. Nuclei were spun down and the supernatant
was saved as cytosolic fraction. The nuclear pellet was
resuspended into 100 µl of Buffer C [20 mM HEPES (pH
7.9), 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM PMSF and 0.5 mM DTT], sonicated to
decrease viscosity and rotated in the cold room for 30
min. Ultracentrifugation was performed to remove insol-
uble debris, and supernatant used as nuclear extract.
Nuclear proteins were quantified by the commercial Bio-
Rad protein assay, and EMSA was performed as described
previously [28].
Results
Ectopic IkBα expression does not affect the development 
of granulocytes, monocyte, and T cell lineages
To assess the role of NF-kB during B cell development, a
trans-dominant form of the NF-kB inhibitor, IkBα, was
constructed into a GFP-containing retroviral vector,
MIGR1 [39,40,42] and used for bone marrow infection
and transfer experiments (Supplemental Figure 8 and Fig-
ure 9). The IkBα and control viruses were obtained by co-
transfecting the expression vectors with the packaging
plasmids into 293T cells. Viral titer was determined by
infecting NIH3T3 cells. In a typical experiment, the trans-
fection efficiency of MIGR1 and IkBα plasmids reached
68–76% in 293T cells (Figure 1A) with viral titers in the
range of 1–5 × 107/ml as determined on 3T3 cells (Figure
1B). Bone marrow cells derived from 5-FU treated mice
were then infected with retroviruses in culture for 48
hours. Roughly 60–90% infection efficiency of bone mar-
row cells infected with both MIGR1 and IkBα viruses was
achieved prior to transfer into lethally-irradiated recipient
mice (Figure 1C).
Recipient chimeras were next analyzed at two and four
weeks post bone marrow transfer. Bone marrow and
spleen cells from the recipients were stained with various
hematopoietic lineage markers and analyzed by flow
cytometry. Chimeric mice receiving the control MIGR1-
infected bone marrows reconstituted with granulocytes
and macrophages within normal range as the non-manip-
ulated control mice. The percentage of Gr1+ and Mac1+
cells are comparable in both GFP+ or GFP- populations of
the MIGR1 reconstituted recipients, suggesting that
MIGR1 (and GFP expression) control virus did not affect
the differentiation of these cell lineages. By contrast, chi-
meras receiving the IkBα-infected bone marrow cellsMedical Immunology 2004, 3 http://www.medimmunol.com/content/3/1/1
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Bcl-X expression significantly improves B cell viability but is insufficient to drive the maturation of transitional B cells Figure 5
Bcl-X expression significantly improves B cell viability but is insufficient to drive the maturation of transitional 
B cells Bone marrow derived from Bcl-X transgenic (WTtg) and non-transgenic (WT) mice were infected with MIGR1 con-
trol and IkBα-viruses in vitro and transferred to lethally-irradiated recipients. Splenocytes were isolated from the MIGR1 con-
trol and IkBα-transduced chimeras two and four weeks after bone marrow transplantation. (A) Cells were stained with PE-
conjugated B220 antibody and analyzed by flow cytometry. (B) Cells were co-stained with biotin-conjugated CD21 and PE-
conjugated CD23 antibodies and analyzed by flow cytometry. After gating on GFP+ population, the percentage of follicular B 
cells (CD21+/CD23+), marginal zone B cells (CD21+/CD23-), and transitional B cells (CD21-/CD23-) were enumerated. (C) 
Cells were co-stained with biotin-conjugated CD24 and PE-conjugated IgM antibodies and analyzed by flow cytometry. After 
gating on GFP+ cells, the percentage of Transitional immature B cells (CD24-hi, IgM+) and mature B cells (CD24-lo, IgM+) 
were enumerated.
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appeared to have a slightly higher percentage of Gr1+ and
Mac1+ cells in the GFP+ population than in the GFP-
population in both bone marrow and spleen (data not
shown). This apparent increase in granulocyte and mono-
cyte ratio, in IkBα-expressing (GFP+) population, corre-
lated with the dramatic decrease in B cell numbers (see
below). The total cell number in bone marrow and
spleens were comparable in MIGR1 and IkBα reconsti-
tuted recipients (Figure 7).
The development of the T cell compartment was also
examined by staining the bone marrow, spleen, and thy-
mus with CD4 and CD8 antibodies. As expected, bone
marrow contains very few CD4 or CD8 positive cells.
However, in the spleen, IkBα expression slightly decreased
the CD4 and CD8 single positive T cell percentage. Repop-
ulation of thymocytes in the thymus became visible four
weeks post-transfer. Interestingly, IkBα expression in the T
cell lineage did not grossly affect the percentage of CD4/
CD8 double positive, double negative, or single positive
population despite high viral transduction efficiency
(greater than 84% cells were GFP+) (data not shown).
Because these results are reproducible among several inde-
pendent experiments, our data suggest that NF-kB does
not play a major role in T cell development, contrary to its
observed effects on B cell development (see below).
Ectopic IkBα expression severely blocks B cell 
development in the bone marrow
B cell development was next examined using various B cell
markers. Chimeras reconstituted with the IkBα-expressing
bone marrow had dramatically reduced numbers of
B220+ cells in the bone marrow and spleen as compared
to those receiving MIGR1-infected control BM cells (Fig-
ure 2A). Whereas we observed a reconstitution level of
83% in BM and 86% in spleen of B220+ cells within the
GFP+ population of MIGR1 chimeras, there was only 55%
in BM and 21% in spleen of B220+ cells in the GFP+ pop-
ulation of IkBα-transduced chimeras (Figure 2A). These
results suggest that ectopic IkBα expression affects early B
cell development beginning in the bone marrow. Moreo-
ver, the lower percentage of B cells in the spleen than in
the bone marrow suggests a further deficiency as imma-
ture B cells emerge into the periphery (Figure 7).
Model for the roles of NF-kB members in B cell development Figure 6
Model for the roles of NF-kB members in B cell development Distinct NF-kB members are employed at different 
stages of B cell development. Previous studies indicate that p50 and p65 are likely involved in the Pre-BCR-mediated differenti-
ation process, including the Ig light chain expression. C-Rel expression becomes detectable following Pre-B to immature B cell 
differentiation [38]. Meanwhile, p50 and p52 members are critical for the survival and differentiation of Transitional B cells, par-
ticularly in response to Blys signals. The final maturation of late-stage T2 B cells into follicular B cells also requires BCR signals 
that induce p65 and c-Rel activity. In mature B cells, the c-Rel complexes are especially important for BCR-mediated survival 
and cell cycle progression. All NF-kB members have been shown to participate in Ig class switching.
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To trace the effect of IkBα on B cell progenitors, bone mar-
row cells were co-stained with B220 and CD43 antibodies
to determine the percentage of cells at pro-B and pre-B
stages. As shown in Figure 2B, the percentage of B220+/
CD43- pre-B/immature B cells in the IkBα transduced chi-
meras is significantly lower than that of the MIGR1 con-
trol chimeras (47% vs. 70%). By comparison, the
percentage of the B220+/CD43+ pro-B cells is comparable
in the IkBα and MIGR1 transduced chimeras (16% vs.
15%). These results indicate that IkBα expression inter-
feres with the pro-B to pre-B transition, which coincides
with the requirement of the pre-BCR signals for further
differentiation into immature B cells.
IkBα expression also arrests B cell maturation in the 
periphery
In the IkBα transduced chimeras, decreased B cell num-
bers are also observed in the periphery, and to much
greater extent than in the bone marrow (21% vs 55%, Fig-
ure 2A), indicating additional deficiency occurring after
immature B cells have emigrated from the bone marrow.
To further analyze this defect, we examined B cell subsets
in the spleen for the presence of different B cell subsets.
Purified splenic B cells (>95% B220+) derived from both
MIGR1 and IkBα transduced chimeras were co-stained
with CD21 and CD23 antibodies. GFP+ populations were
further gated into follicular (CD21+/CD23+), marginal
zone (CD21+/CD23-) and immature (CD21-/CD23-) B
cell subsets. As shown in Figure 3A, follicular B cells are
significantly reduced in the IkBα transduced chimeras as
compared to the MIGR1 controls (34% in the IkBα group
vs. 54% in the MIGR1 group), correlating with increased
numbers of immature B cells (58% of CD21-, CD23-)
occurring in the IkBα-transduced chimera than in the con-
trol group (36%). In addition, IkBα chimeras had slightly
reduced levels of marginal zone B cells versus controls
(2% vs. 7%). Together, these results demonstrate that
IkBα expression affects B cell maturation into follicular
and marginal zone B cells.
The developmental block at the immature B cell stage
imposed by IkBα expression was further supported by
staining purified splenic B cells with additional markers:
CD24, CD21, and IgM. Immature B cells express high
CD24 levels compared to low levels expressed by the
mature B cells. When the GFP+ populations were further
analyzed for CD24 and IgM levels, it was evident that 60%
of cells were of the immature B phenotype (CD24-hi,
IgM+) in the IkBα-transduced chimeras compared to only
29% in the MIGR1 control group at four weeks post trans-
fer (Figure 3B, bottom panels). Accordingly, the percent-
age of mature B cells (CD24-lo, IgM+) is lower in the IkBα
group (13%) than in the MIGR1 control group (42%). At
two weeks post-transfer, most B cells expressed high CD24
levels, indicative of their immature phenotype (Figure 3B,
top panels).
Immature B cells can be further divided into transitional
1 (T1) and T2 types based on the CD21 and CD23 expres-
sion. Whereas the T1-B cells are negative for both markers
(CD21-, CD23-), T2-B cells express both markers (CD21+,
CD23+). To facilitate the identification of these B cell sub-
sets, purified splenic B cells were co-stained with CD21
and IgM. GFP+ populations were further gated and ana-
lyzed for the CD21 and IgM expression levels. As shown
in Figure 3C, there is a greater percentage of T1-B cells in
the IkBα-transduced chimeras than the MIGR1 controls
(31% vs. 19%) and a lower percentage of more mature
(T2, follicular, and MZ) B cell populations in the IkBα
group compared to control group (44% vs. 50%).
Collectively, these data demonstrate that ectopic IkBα
expression affects B cell development at two checkpoints:
it impairs the pro-B to pre-B transition in the bone mar-
row, and causes a developmental arrest of B cell matura-
tion in the periphery with reduced mature follicular B cells
and marginal B cells.
Bcl-X transgene rescues the pre-B deficiency imposed by 
IkBα expression
The majority of the NF-kB-mediated biological activities
have been attributed to the regulation of cell survival
genes by NF-kB proteins [43-48]. In addition to providing
survival signals, certain NF-kB members have also been
shown to participate in cell cycle, differentiation, and
effector functions in immune cells [8,49-51]. For exam-
ple, c-Rel deletion leads to impaired cell cycle progression
that is independent of cell survival defect in B-lym-
phocytes [49,51]. RelB and p50/p65 are required for den-
dritic cell differentiation [52-55], whereas p50/c-Rel
deletion impairs only mature dendritic cell cytokine pro-
duction and costimulation function without affecting dif-
ferentiation [55,56].
It is therefore important to discern whether NF-kB con-
tributes to B cell development through maintaining B cell
survival and/or regulating differentiation processes. To
address this issue, we utilized Bcl-X transgenic mice that
preferentially express Bcl-X in the B cell lineage
[47,57,58]. Bone marrow cells derived from Bcl-X trans-
genic mice (as well as non-transgenic control mice) were
infected with IkBα or MIGR1 retroviruses as described
above, and transferred into irradiated recipients. Bone
marrow and spleen of the chimeric mice were then ana-
lyzed two or four weeks after reconstitution. Consistent
with the above findings, IkBα transduced chimeras had a
reduced percentage of B220+ cells in the bone marrow. By
gating on GFP+ populations, only 51% B220+ cells were
detected in the IkBα-expressing BM cells as compared toMedical Immunology 2004, 3 http://www.medimmunol.com/content/3/1/1
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71% B220+ cells in the MIGR1 reconstituted chimeras
(Figure 4A). Interestingly however, the Bcl-X transgene
expression completely restored B cell percentage in the
IkBα-transduced chimeras (Figure 7). B220+ cells within
the GFP+ populations were 57% and 64% in the MIGR1
and the IkBα-chimeras, respectively. A similar trend was
observed for chimeras analyzed two weeks post transfer
(Figure 4A, four panels on the left).
Further analysis of the B cell precursors using CD43 and
B220 double staining revealed that, among the GFP+ pop-
ulations, IkBα overexpression severely reduced the per-
centage of Pre-B/immature B cells (16%) compared to
MIGR1 control (55%) at four weeks post reconstitution
(Figure 4B, four panels on the right). Intriguingly, the Bcl-
X transgene completely restored the Pre-B/immature B cell
population in IkBα-transduced chimeras (40%) to
MIRG1 control levels (39%). These results thus suggested
that the IkBα-transduced Pre-B/immature B cell develop-
mental block resulted from diminished cell viability.
Bcl-X transgene rescues the viability of immature B cells 
but fails to override the maturation block imposed by IkBα 
expression
The effect of Bcl-X transgene on B cell maturation in
periphery was further analyzed in the spleens of chimeric
Total and GFP+ cell numbers in the bone marrow and spleens of virus-transduced bone marrow chimeras Figure 7
Total and GFP+ cell numbers in the bone marrow and spleens of virus-transduced bone marrow chimeras. 
Total cell number and percentage of GFP+ cells in the bone marrow and spleen of individual chimera was determined.  WTtg-
MIGR1 and WTtg-IkB represent the Bcl-X transgenic mice that were transduced with MIGR1 and IkBa virus, respectively.  Sta-
tistical analysis was performed on combined data from all chimeras used in several independent experiments.  The GFP+ cell 
number was calculated by multiplying the total cell number with the GFP+ percentage.  The number in the parentheses repre-
sents the percentage of cell numbers in the IkBa group over the cell number in the MIGR1 group (100%).  ND: Not 
determined.
Tissue WTtg-MIGR1 MIGR1 WTtg-IkB IkBα
TN: total cell number
TN BM 14.7±9.1
(100%)
15.3 ±11
(104%)
29
(100%)
31
(106%)
38.7±22
(100%)
65.3 ±25.7
(167%)
38
(100%)
33
(87%)
GFP+ 8.2±8.1
(100%)
5.0 ±4.6
(63%)
24.6
(100%)
21.2
(85%)
23.3±19.2
(100%)
5.5 ±0.3
(24%)
25
(100%)
16.4
(66%)
Spleen 58.3±41
(100%)
44.3 ±32.8
(76%)
49
(100%)
32
(65%)
TN
143.3±20.8
(100%)
109 ±57.3
(76%)
190
(100%)
130
(68%)
32.2±22.2
(100%)
8.6 ±4.2
(27%)
GFP+
69.4±47.7
(100%)
14.2 ±9.9
(20%)
127.5
(100%)
59.5
(47%)
ND ND
2Wks
4Wks
TN BM
GFP+
Spleen TN
GFP+Medical Immunology 2004, 3 http://www.medimmunol.com/content/3/1/1
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mice at four weeks post reconstitution. Consistent with
previous results (Figure 2A), there was a significant
decline in the B220+ cell percentage within the splenic
GFP+ population of the IkBα-transduced chimeras (45%)
compared to MIGR1 transduced chimeras (85%) (Figure
5A). Bcl-X transgene was able to restore majority of B220+
cells in the spleen of IkBα transduced chimeras (78% as
compared to 89% in MIGR1 samples), suggesting that
IkBα induced loss of peripheral B cells occurs via apopto-
sis. However, when B cell subsets were further analyzed, it
was evident that B cell maturation was not fully restored.
Staining of the purified splenic B cells (>95% B220+) with
CD21 and CD23 (and further gating for GFP+ popula-
tion) revealed that follicular B cells constitute 64% and
87% of total B cells in the chimeras receiving the control
wild type and in Bcl-X transgenic bone marrow, respec-
tively (Figure 5B, two panels on the left). However, the
IkBα-transduced bone marrow chimeras had reduced fol-
licular B cells (49%) (Figure 5B). Interestingly, although
the Bcl-X transgene rescued peripheral B cell numbers in
the IkBα-transduced chimeras (Figure 7, data not shown),
only 16% of the B cells consist of follicular mature B cells.
The majority of the rescued B cells were arrested at the
immature B cell stage (75%) (Figure 5B). Using additional
markers including CD24, CD21, and IgM, we reached
similar conclusions where we observed that a relatively
high percentage (44% for WT, 38% for WTtg) of B cells
exhibited immature phenotype (CD24-hi, IgM+, or
CD21-, IgM+) in IkBα-transduced chimeras compared to
control groups (15% for WT, 23% for WTtg) (Figures 5C
and data not shown). The mature B cell percentage was
significantly reduced in IkBα-transduced chimeras regard-
MIGR1-IkBa construct  Figure 8
MIGR1-IkBa construct. The cDNA encoding human IkBa (from aas 38-280) was cloned into the Bgl II and EcoRI sites of the 
MIGR1 retroviral plasmid [36, 37].  The expression of IkBa was confirmed by western blot analysis of transfected 293 cell line 
(data not shown).
IkBα
EcoR I
Bgl IIMedical Immunology 2004, 3 http://www.medimmunol.com/content/3/1/1
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less of Bcl-X expression (17% for WT, 19% for WTtg) as
compared to control samples (59% for WT, 52% for
WTtg). Therefore, despite significantly improved cell via-
bility and cell number, Bcl-X expression is insufficient to
override the maturation block imposed by IkBα protein
expression. These data suggest that NF-kB not only pro-
vide survival signals for immature B cells but also is
required for the final maturation of follicular B cells in the
periphery.
Discussion
In this study, we address the role of NF-kB in B-cell lym-
phopoiesis and differentiation by introducing a pan-NF-
kB inhibitor with retroviral transduction and bone mar-
row transfer approaches. Our data demonstrate that NF-
kB inhibition affects B cell differentiation at the pro-B to
pre-B cell transition. An additional impairment is
observed in the periphery where the survival and matura-
tion of transitional immature B cells is affected. Interest-
ingly, Bcl-X expression can rescue the defect at the pre-B
stage and significantly increases the number of transi-
tional B cells in the spleen. Nonetheless, these peripheral
B cells remain arrested at the immature stage. This study
suggests that NF-kB activity is required not only for the
overall survival of B cells at all developmental stages, but
also for the maturation of transitional B cells into follicu-
lar B cells in the periphery.
Numerous studies have established the contribution of
pre-BCR and BCR signals in B cell development and sur-
vival. Deletions of the Igµ or Igα/β chains lead to develop-
mental arrest at the pro-B stage, suggesting that the pre-
BCR signals are essential for inducing Ig light chain gene
rearrangement and differentiation into pre-B and imma-
ture B cells [18-20]. Supporting this notion is the finding
that in vivo occupancy of the κB site is observed by in vivo
footprinting analysis of the Igκ intronic enhancer in pri-
mary pro-B and pre-B cells [38]. This observation is con-
sistent with our finding that IkBα expression blocks Pro-B
to Pre-B cell stage transition, as NF-kB inhibition should
prevent Igκ gene expression and perturb the assembly of
IgM on cell surface.
Targeted disruption of the surface BCR on mature B cells
results in rapid cell death, indicating that the basal BCR
activity is required for maintaining the survival of resting
mature B cells [21]. Further studies on downstream sign-
aling molecules have suggested more elaborate develop-
mental controls after the emigration of immature B cells
to the periphery. Ablation of many of the signaling com-
ponents (e.g. tyrosine kinases, adaptor molecules) and
downstream transcription factors (e.g. NF-kB) affects the
final maturation of transitional immature B cells [22]. For
example, deletion of the Syk kinase completely blocks the
maturation of transitional B cells into recirculating follic-
ular B cells [59]. On the other hand, expression of Bcl-2
results in a greater accumulation of immature B cells both
in the bone marrow and in spleen, however, these cells
retain a the transitional B cell phenotype. These observa-
tions are remarkably similar to our findings using IkBα-
transduced bone marrow chimeras, thus suggesting that
Syk and NF-kB are likely to fall in the same signaling
pathway.
While the exact mechanism governing the maturation of
transitional T1, T2, into follicular or marginal zone B cells
is still unclear, knockout studies have identified genes that
are involved in these processes. For example, Blys(-/-)
mice have normal levels of T1 cells, but lack T2, marginal
zone, and follicular mature B cells in the periphery
[60,61]. This phenotype is mimicked by that of the NF-kB
p50/p52 double knockout mice. In fact, Blys has been
shown to induce p100 processing and the generation of
active p52 complexes, further supporting the role of these
NF-kB members (p50, p52) in T1 to T2 transition [26,27].
A few studies have also shown that the late-stage T2 cells
may require both Blys and BCR signals for differentiation
Inhibition of NF-kB binding activity in splenic B cells derived  from MIGR1 and IkBa transduced chimeras Figure 9
Inhibition of NF-kB binding activity in splenic B cells 
derived from MIGR1 and IkBa transduced chimeras. 
Splenic B cells were purified from MIGR1 control or IkBa 
virus-transduced bone marrow chimeras and treated with 
medium, anti-CD40, or anti-IgM for 4 hours.  Nuclear 
extracts were prepared from the cells and analyzed by EMSA 
using 32P-labeled IgkB oligonucleotides as described in Mate-
rials and Methods.  The transduction efficiency for MIGR1 
control or IkBa virus-transduced cells used for this particular 
experiment is 29% and 15%, respectively.  IkBa transduced B 
cells exhibit decreased NF-kB DNA binding activity, confirm-
ing that the IkBa described in the paper is a biological active 
inhibitor.
B cells 
(MIGR1)
B cells 
(IkBα)
Medium α-CD40 α-IgM Medium α-CD40 α-IgMMedical Immunology 2004, 3 http://www.medimmunol.com/content/3/1/1
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into follicular mature B cells [17]. This is consistent with
the observation that many of the gene-targeted deletions
of BCR signaling components affect the differentiation
into the IgM-lo/IgD-hi follicular mature B cell stage,
including Lyn, Btk, PLC-γ2, BCAP, vav, PI3K (p85,
p110δ), and PKCβ [22,62]. Coincidently, these signaling
molecules have been shown to regulate conventional NF-
kB activation. Thus, it is of interest to note that the final
maturation from late-stage T2 cells to follicular B cells
requires BCR-dependent NF-kB mediated differentiation
signaling, as survival signal provided by Blys or Bcl-X
alone is insufficient to complete the maturation processes.
This notion is further supported by our data showing that
Bcl-X restores the transitional B cell number, but is unable
to induce the maturation of these cells into follicular B
cells. Furthermore, studies on NF-kB p65/c-Rel and p50/c-
Rel double knockout mice are consistent with the view
that these conventional NF-kB complexes are required for
the generation of follicular mature B cells [33,35].
Based on previous NF-kB knockout mouse studies and the
findings from this report, we propose the following model
to describe the roles of distinct NF-kB members in B cell
differentiation (see Figure 6, Model). In the bone marrow,
the Pre-BCR signals are required for Ig light chain expres-
sion and the assembly of IgM, which marks the differenti-
ation of immature B cells. The p50 and p65 NF-kB
members are particularly important in mediating the Pre-
BCR signaling and may participate in the regulation of Igκ
gene expression. In the periphery, Blys-mediated survival
signals of transitional B cells absolutely require the pres-
ence of p52. Blys signals may eventually cooperate with
BCR signals (via p65, c-Rel) in driving maturation into the
follicular B cells. Mature B cells critically depend on c-Rel
complexes to regulate cell survival and cell cycle programs
upon recognition of antigens by BCR on the cell surface.
It is somewhat surprising to us that the IkBα expression
does not grossly affect thymocyte development. Our find-
ing, however, is consistent with several reports using IkBα
transgenic mice. According to one study, double positive
(DP) CD4+ CD8+ T cell development is normal in IkBα
transgenic mice but single positive (SP) populations are
significantly reduced [63], whereas in another study only
CD8+ thymocytes were affected [64]. In both studies,
peripheral CD4 and CD8 T cell numbers were severely
diminished. Similar results have been obtained in p65-c-
Rel double knockout that deletion of both c-Rel and p65
leads to only decreased peripheral CD4+ and CD8+ T cell
numbers without affecting early T cell development
[34,65]. Moreover, a detailed analysis of IkBα transgenic
double negative (DN) thymocytes has revealed a specific
reduction in the number of DN-IV stage thymocytes. The
subtle differences in these studies could be attributed to
differing levels of IkBα expression. In addition, Lck medi-
ated expression of IkBα gene may be more specifically tar-
geted to T cell precursors, whereas these precursors may be
under-represented in the bone marrow cultures as used in
this report.
Our findings detailed in this report point towards the
rational for the development of new pharmaceutical
agents that mimic the effect of glucocorticoids on the
activation of IkB that could function to be effective immu-
nosuppressive drugs. Conversely, agents that target the
suppression or removal of IkB in lymphoid cells could be
developed as immunopotentiating compounds.
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